Menu Search
Equities

Equasens SA

PHF:FRA

Equasens SA

Actions
  • Price (EUR)57.60
  • Today's Change-1.50 / -2.54%
  • Shares traded34.00
  • 1 Year change-18.07%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024 14:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Equasens SA is formerly known as Pharmagest Interactive SA is a France-based company. The Company is engaged in the development and integration of management software packages for drugstores. It offers all IT (Information Technology) and High-Tech fields related to Health and in specialized fields which are associated to it such as IT for pharmacies, solutions for e-Health, solutions for pharmaceutical industry, solutions for patients etc. The Company operates in four divisions that includes Europe Pharmacy Solutions Division including France Pharmacy Section and Belgium and Luxembourg Pharmacy Section, Solutions for sanitary and medico-social entities Division, e-Health Solutions Division including e-Laboratories section, e-Patients section and e-Connect section and Fintech Division.

  • Revenue in EUR (TTM)223.12m
  • Net income in EUR48.50m
  • Incorporated1996
  • Employees1.22k
  • Location
    Equasens SA5 Allee de Saint-CloudVILLERS LES NANCY 54600FranceFRA
  • Phone+33 383159595
  • Fax+33 383159805
  • Websitehttps://equasens.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		EQS:PAR since
announced		Transaction
value
SARL DigipharmacieAnnounced02 Jan 202402 Jan 2024Announced-5.07%--
Data delayed at least 15 minutes, as of Apr 26 2024 16:35 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.